Compare Cipla with Biocon - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs BIOCON - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA BIOCON CIPLA/
BIOCON
 
P/E (TTM) x 35.7 30.5 116.9% View Chart
P/BV x 4.1 3.9 107.1% View Chart
Dividend Yield % 0.5 0.3 194.2%  

Financials

 CIPLA   BIOCON
EQUITY SHARE DATA
    CIPLA
Mar-20
BIOCON
Mar-19
CIPLA/
BIOCON
5-Yr Chart
Click to enlarge
High Rs586707 82.8%   
Low Rs357554 64.4%   
Sales per share (Unadj.) Rs207.091.9 225.3%  
Earnings per share (Unadj.) Rs18.616.7 111.3%  
Cash flow per share (Unadj.) Rs33.224.2 137.2%  
Dividends per share (Unadj.) Rs4.001.00 400.0%  
Dividend yield (eoy) %0.80.2 535.3%  
Book value per share (Unadj.) Rs195.5101.6 192.3%  
Shares outstanding (eoy) m806.35600.00 134.4%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.36.9 33.2%   
Avg P/E ratio x25.337.7 67.1%  
P/CF ratio (eoy) x14.226.1 54.5%  
Price / Book Value ratio x2.46.2 38.8%  
Dividend payout %21.56.0 359.4%   
Avg Mkt Cap Rs m379,912378,330 100.4%   
No. of employees `00025.86.1 421.5%   
Total wages/salary Rs m30,27011,653 259.8%   
Avg. sales/employee Rs Th6,459.68,994.3 71.8%   
Avg. wages/employee Rs Th1,171.21,900.7 61.6%   
Avg. net profit/employee Rs Th580.21,635.3 35.5%   
INCOME DATA
Net Sales Rs m166,94955,144 302.8%  
Other income Rs m3,4421,444 238.4%   
Total revenues Rs m170,39156,588 301.1%   
Gross profit Rs m32,06015,883 201.9%  
Depreciation Rs m11,7474,478 262.3%   
Interest Rs m1,974709 278.4%   
Profit before tax Rs m21,78212,140 179.4%   
Minority Interest Rs m-4759 -5,273.3%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6,3122,123 297.3%   
Profit after tax Rs m14,99510,026 149.6%  
Gross profit margin %19.228.8 66.7%  
Effective tax rate %29.017.5 165.7%   
Net profit margin %9.018.2 49.4%  
BALANCE SHEET DATA
Current assets Rs m117,03848,228 242.7%   
Current liabilities Rs m43,93130,376 144.6%   
Net working cap to sales %43.832.4 135.3%  
Current ratio x2.71.6 167.8%  
Inventory Days Days9668 140.2%  
Debtors Days Days8586 99.5%  
Net fixed assets Rs m107,42464,130 167.5%   
Share capital Rs m1,6133,000 53.8%   
"Free" reserves Rs m156,01857,980 269.1%   
Net worth Rs m157,63060,980 258.5%   
Long term debt Rs m23,69315,766 150.3%   
Total assets Rs m236,626121,924 194.1%  
Interest coverage x12.018.1 66.4%   
Debt to equity ratio x0.20.3 58.1%  
Sales to assets ratio x0.70.5 156.0%   
Return on assets %7.28.8 81.4%  
Return on equity %9.516.4 57.9%  
Return on capital %12.816.8 76.6%  
Exports to sales %33.028.1 117.5%   
Imports to sales %018.9 0.0%   
Exports (fob) Rs m55,17515,506 355.8%   
Imports (cif) Rs mNA10,399 0.0%   
Fx inflow Rs m56,03615,506 361.4%   
Fx outflow Rs m6,76410,399 65.0%   
Net fx Rs m49,2725,107 964.8%   
CASH FLOW
From Operations Rs m30,68511,546 265.8%  
From Investments Rs m1,040-7,138 -14.6%  
From Financial Activity Rs m-29,488-2,417 1,220.0%  
Net Cashflow Rs m2,3402,103 111.3%  

Share Holding

Indian Promoters % 16.0 40.4 39.6%  
Foreign collaborators % 20.8 20.6 101.0%  
Indian inst/Mut Fund % 12.2 8.4 145.2%  
FIIs % 23.7 10.7 221.5%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 19.9 131.7%  
Shareholders   161,166 109,995 146.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   TORRENT PHARMA  ALKEM LABORATORIES  ELDER PHARMA  SANOFI INDIA  ALEMBIC PHARMA  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Plunges 746 Points; Banking & Metal Stocks Bleed(Closing)

Indian share markets witnessed huge selling pressure today and extended losses as the session progressed, dragged down by heavy selling in metal and banking stocks.

Related Views on News

BIOCON Share Price Down by 10%; BSE HEALTHCARE Index Down 1.2% (Market Updates)

Jan 22, 2021 | Updated on Jan 22, 2021

BIOCON share price is trading down by 10% and its current market price is Rs 424. The BSE HEALTHCARE is down by 1.2%. The top gainers in the BSE HEALTHCARE Index are AUROBINDO PHARMA (up 1.7%) and FORTIS HEALTHCARE (up 0.9%). The top losers is BIOCON (down 10.1%).

SRF Share Price Down by 5%; BSE 500 Index Up 0.3% (Market Updates)

Jan 22, 2021 | Updated on Jan 22, 2021

SRF share price is trading down by 5% and its current market price is Rs 5,715. The BSE 500 is up by 0.3%. The top gainers in the BSE 500 Index are JK TYRE & IND (up 14.5%) and CYIENT (up 11.1%). The top losers are SRF (down 5.1%) and BIOCON (down 8.7%).

BIOCON Share Price Down by 6%; BSE HEALTHCARE Index Down 0.2% (Market Updates)

Jan 22, 2021 | Updated on Jan 22, 2021

BIOCON share price is trading down by 6% and its current market price is Rs 424. The BSE HEALTHCARE is down by 0.2%. The top gainers in the BSE HEALTHCARE Index are PROCTER & GAMBLE HEALTH (up 2.6%) and JUBILANT LIFE SCIENCES (up 1.5%). The top losers is BIOCON (down 6.1%).

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 22, 2021 03:36 PM

TRACK CIPLA

CIPLA - ALKEM LABORATORIES COMPARISON

COMPARE CIPLA WITH

MARKET STATS